My PCR Frequently Asked Questions

Similar documents
2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals

TECHNOLOGIES AVAILABLE FOR LICENSING AT UNIVERSITY OF DELHI

More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D.

Andrew Schorr: Dr. Stadtmauer, related to multiple myeloma what is the role of transplant today?

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org

Nanthealth Patient Informed Consent

A LOOK AT WHAT S INSIDE

April transmart v1.2 Case Study for PredicTox

UAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Restrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials

Multiple myeloma and its precursor disease (MGUS)

Reverse-engineering AdWords Quality Score factors

Autologous Infusions Alisha Mussetter Clinical Research Coordinator II Wednesday February 17 th, 2016

Andrew Schorr: Is there anything you ve been discussing that you d like to update people about now?

King George's Medical University UP., Lucknow center for advance research

The Future of Hematological Diagnosis

Dana-Farber Cancer Institute Speeds Medical Research with Advanced Data Warehouse

An innovative approach to genetic testing for improved patient care

Stem Cells: Introduction and Prospects in Regenerative Medicine.

International Myeloma Foundation Myeloma Action Month Proclamation Kit

ADAPTIVE BIOTECHNOLOGIES DIAGNOSTIC PORTAL: ACCOUNT LOGIN

CIBMTR Audits. Deb Christianson, Senior Manager Monitoring and Auditing Matt Petcoff, Senior CRA

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Chapter 8 Healthcare Biotechnology

How do my values influence my career choice? Which career am I most passionate about and why?

Genetic tests are available for hundreds of disorders. DNA testing can pinpoint the exact genetic basis of a disorder.

Agile TesTing MeTrics Quality Before Velocity

Corporate Medical Policy Genetic Testing for Fanconi Anemia

The Cost-Benefit Calculus of CT Angiograms

Go beyond checking compliance boxes Why most internal EHS audits fall short

International Myeloma Foundation Myeloma Action Month Proclamation Kit

Open Enrollment 2014 FAQs Express Script Prescription Drug Plan

Clinical trials patient-education brochure

Transitioning to Express Scripts

Exome Sequencing Exome sequencing is a technique that is used to examine all of the protein-coding regions of the genome.

New Drug Therapies for ITP

Research and Development of Dasatinib. Research and Development Related to dasatinib (Sprycel TM ) KEI Research Note 2008:3

Genetic Resource Centre Roy Romanow Provincial Laboratory

HEALTH CARE PROVIDER TOOLKIT

Genentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers

Leukemia / Bone Marrow Transplant (BMT) Program of British Columbia

Lesson 7A Specialized Cells, Stem Cells & Cellular Differentiation

Change Summary - Form 2116 (R3) 1 of 6

W8 Wednesday, November 3, :15 PM

TWITTER 101: An Introduction for the AASM Member

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing

PV92 PCR Bio Informatics

SOURCES AND RESOURCES:

NEWS RELEASE. FOR IMMEDIATE RELEASE Contact: Thomas Becher ndp

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE

The Digital Employee and You. Adapting HR experiences for the new workforce generations

Statistical Challenges: Designs for clinical trials with limited patient populations

UNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process

A Bid for Every Auction. Implementing and Improving AdWords Automated Bidding

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

The power of influencers. Quantified.

YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING

Real-Time Web Personalization for the busy Ecommerce Professional like you

Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial

Dr. Stephen Kingsmore a vision for transforming medicine with rapid genome sequencing

American Society of Cytopathology Core Curriculum in Molecular Biology

The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.

They Work For Us: A Self-Advocate s Guide to Getting Through to your Elected Officials

to Successful Non-profit Cloud ERP System Selection

Certification in Clinical Molecular Genetics and Genomics Logbook Guidelines for 2019 Examination

White Paper Searchable Data:

Bronx, New York Patient-Caregiver Forum November 1, 2017 Page 1 of 9

DNA: The Code of Life

The following questions and answers have been posted in the order that they have been received:

UNDERSTANDING THE CLONOSEQ ASSAY

Information and resources for African Americans living with multiple myeloma and their caregivers

BIMM18 Dec 20 th - Flow cytometry in clinical diagnostics

The power of influencers. Quantified.

Certification in Laboratory Genetics and Genomics Logbook Guidelines 2019 Examination

Related Donor Informed Consent to Participate in Research

An Introductory Guide. For Clinicians & Service Managers IMPROVING ACCESS TO PSYCHOLOGICAL THERAPIES SERVICES START HERE

Patient Handbook on Stem Cell Therapies

HCAHPS Readiness and Performance Management White Paper

R O EVIE NL 1 INE WS Why They Matter

Statements on the Regulation of Laboratory Developed Tests

Mutations, Genetic Testing and Engineering

Cytogenetics. Revised effective July 14, Cytogenetics Standard 1 (CG S1)

BEFORE, DURING AND AFTER A STEM CELL TRANSPLANT

LIGHTING THE PATIENT PATHWAY. How to bridge the audience divide in pharmaceutical marketing HEALTH GROUP

What is the purpose of the Tissue Bank and the Research it will be used for?

The Latest Therapies for MS: Weighing Respective Benefits and Risks

Name... Class... Date... In this activity you are going to assess the quality of some science articles written for different publications.

Lead the way. Molecular Imaging. GE Healthcare. imagination at work

KNOW HOW TO TALK WITH YOUR TEEN ABOUT INSTAGRAM:

AMERICAN BOARD OF MEDICAL GENETICS

Bone Marrow Failure Research Program

Fluorescent in-situ Hybridization

What is Precision Medicine?

PMT. Explain how the differences between the DNA sequences from the quagga and the mountain zebra may have arisen as a result of mutation

Molecular Diagnostics

Agent vs. Agentless Discovery Guide: Choosing the Right Solution for Your IT Assets

Marsh ClearSight LLC is a business unit of Marsh LLC, the global leader in insurance broking and risk management.

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

Transcription:

My PCR Frequently Asked Questions

Dear friend, This Frequently Asked Questions (FAQ) booklet has been created for you as part of the My PCR. The booklet contains FAQs prepared by chronic myeloid leukemia (CML) expert, Dr. Michael Mauro, as a place to track your PCR test results, as well as a space for notes. In addition to this booklet, we invite you to visit the campaign website at to access other PCR resources such as educational information about PCR testing and the International Scale, key questions about PCR testing to discuss with your physician and additional tools for tracking your test results. If you have not already done so, we also encourage you to join the campaign through the website to receive email notifications about campaign updates. Joining the campaign is way to support the rights of patients to know their PCR levels! With thanks, My PCR Partners

What is My PCR? Frequently Asked Questions Written by Michael J. Mauro, M.D. Leader, Myeloproliferative Disorders Program Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Content compiled by The Max Foundation September 2012

Q.1 What is PCR? PCR stands for polymerase chain reaction. It is a diagnostic and monitoring tool used in CML to measure the response to treatment. It is not only used in CML; PCR is also used in other conditions and is generally one of or the most sensitive ways to detect something; for example, BCR-ABL can be detected in a person with CML, anthrax on a mailed letter, or evidence of a specific virus in a person after bone marrow transplant. Q.2 Why should I know my PCR level? Every time the PCR is run the value is important, and conveniently can be compared to prior values. It often is the only test which gives someone an idea about the depth and stability of their response to treatment. A person with CML should always know their PCR level! PCR results should be explained to patients in as much depth as they can understand, so they have a good sense about the response level, how this compares to where they should be, when the next test is due and if any concern or risk has developed. ASK! Q.3 What does PCR measure in CML? CML occurs when a specific change happens between chromosomes 9 and 22; parts of them swap places, creating a protein called BCR-ABL (Philadelphia Chromosome). This BCR-ABL protein is what makes leukemia blood cells different and malignant. In CML, PCR measures the amount of genetic material (called RNA or DNA) or blueprints for BCR-ABL present; PCR levels are thus linked to both the amount and activity of leukemia cells remaining in someone with CML. PCR is often said to measure the residual (remaining) disease as it can detect very small levels of BCR-ABL blueprints.

Q.4 Is PCR performed from peripheral blood or bone marrow? PCR can be performed from either blood or bone marrow samples. Having enough material to test is important so peripheral blood is almost always preferred (and a lot easier to get)! Q.5 Is PCR the only test I should have done during my treatment? PCR is a powerful tool in CML but it is not the only test needed during treatment. A bone marrow test is recommended at diagnosis to look for accelerated (more aggressive) features in the marrow. A bone marrow test is also the only way to obtain the karyotype, where the chromosomes are examined in a number of cells to count the number with the Philadelphia chromosome (the 9:22 swap, which appears as a long chromosome 9 and short chromosome 22) or to see if any other genetic damage is visible. The karyotype and FISH (fluorescent tagging of cells to count the number with the Philadelphia chromosome) studies are recommended to be repeated until they turn negative (this is called complete cytogenetic remission - or CCyR). Once this milestone is passed and confirmed, the PCR test is the only test that will show residual levels of CML and becomes the main way of monitoring. Q.6 Why is PCR important in the management of CML treatment? PCR is a crucial tool in CML for a number of reasons; first, it is patient friendly, requiring a blood draw only; and second, it is a broad-ranged test, being able to measure untreated (high levels) of BCR-ABL all the way down to the lowest measurable levels.

Q.7 How often should PCR testing be performed? Early in treatment other tests (karyotype and FISH) may take priority over PCR; however, since the overwhelming majority of people with CML normalize their chromosome tests (karyotype and FISH) within the first 12-18 months of treatment, the PCR test becomes most important and is recommended every 3 months once further reduction in BCR-ABL levels occurs (this is referred to as moving from cytogenetic response to major molecular response). Once BCR-ABL levels have fallen at or below the major molecular response, it is recommended to keep monitoring them every 3-6 months to ensure stability and/or further reduction. Q.8 Should my level always be exactly the same? No, if your PCR has changed you should not panic; there appears to be an acceptable degree of fluctuation. However, your doctor must look at your results carefully and focus on the trend overtime. In general, for a CML patient in treatment with a TKI, PCR results over time should be going down. At the beginning of treatment we expect that the PCR levels will usually go down significantly over months. Once the remission milestones are reached, the degree of reduction is generally much smaller and stability is often fine, especially when very deep remission is obtained. A rise in PCR needs to be carefully assessed. One important consideration is the point from which the rise in PCR level occurred. For instance, a rise in PCR for a patient who was in deep molecular remission is different from an increase of the level of PCR in a patient who was not in molecular remission. Likewise, the degree of change, minimal or significant, is also an important consideration. Finally, change that leads to a loss of response, such as loss of a major molecular response, needs close assessment and often at this point, other tests should be performed.

Q.9 What is the ideal PCR level? How long will it take to reach the ideal level of my PCR? In CML we like to talk about achieving milestones. An important milestone is a complete cytogenetic remission (CCyR) which is very important and very protective. This is generally the equivalent to a 2-log, or 100 fold drop in the leukemia level. Additional protection clearly appears to be gained with further reduction in the PCR level to 3 Logs (1000 fold drop) or greater, referred to as a major molecular response (MMR). The MMR level of response is often referred to as a safe haven below which risk of loss of response is the lowest. This being said, the newest TKI therapies increasingly allow patients to achieve deeper responses-4 log and 4.5 log reductions (MR4 and MR4.5). MR4.5 is the level at which measuring the PCR level is difficult in many laboratories, as it no longer detectable or not able to be quantified. This threshold for a period of time was called CMR or complete molecular remission but based on the somewhat misleading nature of that name (as it implies complete response, which to many would mean zero remaining leukemia) there is movement towards simply using the names that describe the level (MR4, MR4.5). Q.10 What can affect my PCR level? PCR levels generally reflect ongoing response to treatment; there may be some variability of the shrinking volume of leukemia, and some variability in the test itself. Because it is a very sensitive test, the same patient might get a different result if measured in two different labs. Another big problem is that all labs do not use the same scale to measure and the exact same level of leukemia could result in different test results in two different labs. Great efforts are being taken to standardize PCR results and report all results on a single (International) scale. The first thing to look at, if the PCR result is different from the last one is where the tests were done (same lab, different lab) and is the International scale being used.

Of course adherence/compliance to therapy (taking medicines for CML) is vital to stable or improving PCR results and one of the first questions physicians and patients need to ask if the PCR level has changed is about therapy -has it been missed or stopped for any reason. Patients who stop taking their treatment daily are more likely to have higher PCR levels and patients who miss even a modest amount of doses early in treatment are less likely to get into deep remission. Q.11 My last PCR has gone up; does this mean my treatment is not working? Not necessarily, but rising PCR needs to be taken seriously. The checklist that needs to be reviewed with any change includes: the range from which the rise has been detected (in cytogenetic remission or not, in molecular remission or not), the degree of change (modest change, change leading to categorical loss of response like for instance, loss of MMR), and the history of the PCR stability to date. Often a rise in PCR prompts a repeat of the PCR at 4-6 weeks to see if the change is sustained and/or confirmed. Q.12 Should my PCR always be done in the same lab? Ideally for now, the answer is yes. Having the PCR done in the same lab will mean reporting on the same scale, making tracking progress easier. Once all labs use the same scale (called the International Scale or IS) having the PCR done in the same lab will likely be less important and reporting will be the same globally. Efforts to have that be the case have been ongoing for many years already and hopefully it will soon be a reality.

Q.13 What does MMR mean? MMR is the acronym for major molecular response. MMR means there has been reduction in the PCR level to 3 logs or greater below a standard baseline (1000x reduction). As mentioned above, the combination of achieving the cytogenetic complete remission (CCyR) milestone and the further reduction in PCR levels to MMR levels is often referred to as a safe haven below which risk has been maximally optimized. MMR is the last milestone of response for which improvement in outcome has been demonstrated. This improvement in outcome is tied to reduction in risk of any loss of response as well as lowering risk of progression of the disease. At the moment, any benefits of deeper response than MMR (MR4 and MR4.5) have more theoretical benefit (related to the possibility of stopping therapy someday?) than proven benefit, hence the current goal is to get all patients at least into stable MMR. Q.14 When should I ask for a second opinion about my CML treatment? Anytime you want to. If there is a problem on your current treatment (side effects, response not on track, loss of response), if there is uncertainty over which medication to start with or switch to, specific or unusual side effects, etc. these are all good reasons. CML is a disease that requires long term treatment, so you should make sure you choose a doctor that is a good fit for you, where you feel you can ask questions, and have an honest and open relationship. There are many CML experts that are truly passionate about working through the details and getting someone back on track, making the right decisions with people about options and explaining things so you can understand and be a part. And they certainly want you to KNOW YOUR PCR!

Chart your PCR test results Date Results

Notes